The role of erythropoietin and erythropoietin receptor expression in breast cancer

被引:0
|
作者
Budzik, M. P. [1 ]
Badowska-Kozakiewicz, A. M. [1 ]
机构
[1] Med Univ Warsaw, Dept Biophys & Human Physiol, Fac Hlth Sci, Warsaw, Poland
关键词
Breast neoplasms; Erythropoietin; Hypoxia; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; RECOMBINANT-HUMAN-ERYTHROPOIETIN; GENE-EXPRESSION; CELL CARCINOMA; EPO RECEPTOR; SURVIVAL; ANEMIA; GROWTH; STAT3; MIGRATION;
D O I
10.12892/ejgo4266.2019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Erythropoietin (EPO) plays a number of important functions in the body. Contrary to original beliefs, its activity is not limited to exerting effects on cells along the erythropoietic pathway. Newly published results continue to provide information on novel functions of the protein in other types of tissues, as well as on the important roles played by EPO in pathological processes. With no doubt, EPO has a significant impact on the biology of breast cancer cells by affecting cells' proliferation, apoptosis, resistance to chemotherapy, as well as expression of various types of receptors. EPO exerts its direct action on breast cancer stem-like cells by activation of specific signaling pathways responsible for protection of the tumor from chemotherapy and accelerating disease progression. EPO could inhibit chemotherapeutic drug-induced apoptosis and cytotoxicity. Its correlation with tissue hypoxia may play a significant role in the therapeutic resistance of hypoxic tumors. In recent years, the role of endogenous EPO in regulation of carcinogenesis was also noted. Exogenous EPO, in the form of rhEPO, had been introduced with best intention to treat patients with cancer-related anemia in the course of breast cancer. While it decreases the transfusion requirements and improves the quality of life of cancer patients, randomized trials have demonstrated that rhEPO administration is associated with shorter progression-free and overall survival. Observations allow also to say that EPO antagonizes treatment with the anti-HER2 antibody trastuzumab by activating EpoR/JAK2 downstream effectors, effectively bypassing HER2 signaling. Although increasing amount of information is available regarding the role of EPO and EpoR in breast cancer, elucidation of the activity and involvement of these proteins in complex processes occurring within the cancer cells requires extensive research. Every set of results being published answers some of the questions while instead raise new ones.
引用
收藏
页码:7 / 15
页数:9
相关论文
共 50 条
  • [41] Heart Failure Remodeling: Local Endogenous Erythropoietin and Erythropoietin Receptor Expression
    Leszek, Przemyslaw
    Sochanowicz, Barbara
    Brzoska, Kamil
    Piotrowski, Walerian
    Danko, Bozena
    Kusmierczyk, Mariusz
    Rozanski, Jacek
    Rywik, Tomasz
    Kruszewski, Marcin
    CIRCULATION RESEARCH, 2012, 111 (04)
  • [42] Erythropoietin and erythropoietin receptor expression in human endometrium throughout the menstrual cycle
    Yokomizo, R
    Matsuzaki, S
    Uehara, S
    Murakami, T
    Yaegashi, N
    Okamura, K
    MOLECULAR HUMAN REPRODUCTION, 2002, 8 (05) : 441 - 446
  • [43] LEVELS OF ENDOGENOUS ERYTHROPOIETIN AND ERYTHROPOIETIN RECEPTOR EXPRESSION IN PATIENTS WITH LYMPHOMAS AND ANAEMIA
    Lyamkina, A.
    Pospelova, T.
    Nechunaeva, I.
    HAEMATOLOGICA, 2012, 97 : 698 - 699
  • [44] Expression of erythropoietin receptor variant forms is associated with lymphatic invasion and metastasis formation in breast cancer
    Rakosy, Z.
    ANNALS OF ONCOLOGY, 2018, 29
  • [45] Erythropoietin and erythropoietin receptor expression after experimental spinal cord injury encourages therapy by exogenous erythropoietin
    Grasso, G
    Sfacteria, A
    Passalacqua, M
    Morabito, A
    Buemi, M
    Macrì, B
    Brines, ML
    Tomasello, F
    NEUROSURGERY, 2005, 56 (04) : 821 - 826
  • [46] Correlation between erythropoietin receptor(s) and estrogen and progesterone receptor expression in different breast cancer cell lines
    Trost, Nina
    Hevir, Neli
    Rizner, Tea Lanisnik
    Debeljak, Natasa
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2013, 31 (03) : 717 - 725
  • [47] EXPRESSION OF ERYTHROPOIETIN RECEPTOR IN ERYTHROLEUKEMIC CELLS
    CASADEVALL, N
    MULLER, O
    CHOPPIN, J
    LACOMBE, C
    GOLDWASSER, E
    TAMBOURIN, P
    VARET, B
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1987, 29 (03): : 184 - 184
  • [48] EXPRESSION CLONING OF THE MURINE ERYTHROPOIETIN RECEPTOR
    DANDREA, AD
    LODISH, HF
    WONG, GG
    CELL, 1989, 57 (02) : 277 - 285
  • [49] Expression of erythropoietin and its receptor in neuroblastomas
    Sartelet, H
    Fabre, M
    Bosq, J
    Racu, I
    Lagonotte, E
    Castaing, M
    Michiels, S
    Vassal, G
    LABORATORY INVESTIGATION, 2006, 86 : 299A - 299A
  • [50] Expression of erythropoietin and its receptor in neuroblastomas
    Sartelet, H
    Fabre, M
    Bosq, J
    Racu, I
    Lagonotte, E
    Castaing, M
    Michiels, S
    Vassal, G
    MODERN PATHOLOGY, 2006, 19 : 299A - 299A